Householder Group Estate & Retirement Specialist LLC Has $1.10 Million Stake in AbbVie Inc. (NYSE:ABBV)

Householder Group Estate & Retirement Specialist LLC lessened its position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 40.6% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 6,169 shares of the company's stock after selling 4,224 shares during the quarter. AbbVie comprises 0.8% of Householder Group Estate & Retirement Specialist LLC's investment portfolio, making the stock its 23rd biggest holding. Householder Group Estate & Retirement Specialist LLC's holdings in AbbVie were worth $1,096,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the company. Quest Partners LLC raised its position in AbbVie by 4,140.0% during the 2nd quarter. Quest Partners LLC now owns 212 shares of the company's stock worth $36,000 after buying an additional 207 shares during the last quarter. Brighton Jones LLC lifted its holdings in shares of AbbVie by 2.5% in the 2nd quarter. Brighton Jones LLC now owns 19,721 shares of the company's stock valued at $3,383,000 after buying an additional 477 shares during the period. Trust Investment Advisors acquired a new stake in AbbVie in the second quarter valued at $242,000. Benjamin F. Edwards & Company Inc. grew its position in AbbVie by 2.2% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 278,306 shares of the company's stock worth $47,735,000 after buying an additional 5,870 shares during the period. Finally, Canada Pension Plan Investment Board lifted its stake in AbbVie by 22.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 2,868,905 shares of the company's stock valued at $492,075,000 after buying an additional 529,707 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company's stock.

AbbVie Price Performance

Shares of ABBV traded down $2.21 during trading hours on Friday, hitting $171.49. 7,581,211 shares of the company were exchanged, compared to its average volume of 4,943,678. The firm has a fifty day simple moving average of $175.78 and a 200-day simple moving average of $184.60. AbbVie Inc. has a one year low of $153.58 and a one year high of $207.32. The company has a debt-to-equity ratio of 9.64, a current ratio of 0.65 and a quick ratio of 0.54. The company has a market capitalization of $303.05 billion, a PE ratio of 59.55, a PEG ratio of 1.73 and a beta of 0.58.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $3.00 earnings per share for the quarter, beating analysts' consensus estimates of $2.92 by $0.08. The business had revenue of $14.46 billion for the quarter, compared to the consensus estimate of $14.28 billion. AbbVie had a return on equity of 244.01% and a net margin of 9.22%. AbbVie's revenue for the quarter was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.95 earnings per share. As a group, sell-side analysts predict that AbbVie Inc. will post 10.06 earnings per share for the current year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be issued a dividend of $1.64 per share. This is a boost from AbbVie's previous quarterly dividend of $1.55. This represents a $6.56 annualized dividend and a dividend yield of 3.83%. The ex-dividend date is Wednesday, January 15th. AbbVie's payout ratio is currently 215.28%.

Analyst Ratings Changes

Several equities analysts recently weighed in on ABBV shares. Daiwa America downgraded AbbVie from a "strong-buy" rating to a "hold" rating in a research report on Thursday, December 5th. BMO Capital Markets reduced their price objective on AbbVie from $228.00 to $208.00 and set an "outperform" rating on the stock in a research note on Tuesday, November 12th. Barclays raised their target price on AbbVie from $200.00 to $212.00 and gave the company an "overweight" rating in a report on Monday, October 7th. Argus upgraded shares of AbbVie from a "hold" rating to a "buy" rating in a report on Monday, November 4th. Finally, Wells Fargo & Company raised their price target on shares of AbbVie to $195.00 and gave the stock a "buy" rating in a research report on Tuesday, November 19th. Five research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, AbbVie presently has a consensus rating of "Moderate Buy" and a consensus price target of $205.50.

Insider Transactions at AbbVie

In other AbbVie news, SVP Kevin K. Buckbee sold 1,800 shares of the stock in a transaction on Monday, December 16th. The shares were sold at an average price of $172.24, for a total transaction of $310,032.00. Following the transaction, the senior vice president now directly owns 6,983 shares of the company's stock, valued at $1,202,751.92. This represents a 20.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.25% of the stock is currently owned by company insiders.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.